approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks ...

1 Elafibranor, a 'first-in-class' molecule marketed and commercialized in the United States, the European Union and the UK by Ipsen under the trademark Iqirvo® since June 2024 for the treatment of ...

Elafibranor, a 'first-in-class' molecule marketed and commercialized in the United States, the European Union and the UK by Ipsen under the trademark Iqirvo® since June 2024 for the treatment of ...

For more information on the press release, click on the following link : Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant ...

Our ESPN Fantasy Football analysts Liz Loza and Matt Bowen offer their analysis of each skill position player selected in the first three rounds of the 2025 NFL draft, and Mike Clay provides his ...

patients has met its primary endpoint of overall remission rate (ORR) at interim analysis. The achievement of the primary endpoint (PDF) milestone triggers a $35 million payment from Blackstone ...